Alivus Life Sciences
Alivus Life Sciences
HealthcareKey Fundamentals
SmallcapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.4%
Weaknesses
2- The company has delivered a poor sales growth of 6.24% over past five years.
- Company has high debtors of 153 days.
Growth Rate
AI Analysis — Bull vs Bear
Alivus Life Sciences, a Healthcare company with a market capitalisation of about ₹16,771 crore, trades at a P/E of 27.9x and P/B of 5.04x. It is almost debt free and earns an ROE of 18-21%, but its 5-year sales CAGR is only 6%. TTM profit growth of 25% is well ahead of TTM sales growth of 8%, while 3-year profit growth is 6% and receivables stand at 153 days.
- TTM profit grew 25%, about three times TTM sales growth of 8%. This suggests operating leverage or margin expansion in the recent period.
- The company is almost debt free, which gives it balance-sheet flexibility for capex or acquisitions without much interest burden or refinancing risk.
- Return on equity has stayed high: 21% over 5 years, 19% over 3 years and 18% last year. This points to capital-efficient operations.
- TTM sales growth of 8% is faster than the 3-year and 5-year sales CAGR of 6%, which may mean top-line momentum is picking up.
- The company has kept a dividend payout ratio of 27.4%. It returns cash to shareholders while keeping most earnings for reinvestment.
- The stock has compounded 30% annually over 3 years and returned 45% over the past year, showing strong market interest in the business.
- A P/E of 27.9x is not extreme for a debt-free Healthcare business with an ROE of about 18%, especially if TTM profit growth of 25% continues.
- Sales grew at only 6.24% a year over 5 years and 6% over 3 years. That is slow growth for a company valued at about ₹16,771 crore.
- Receivables of 153 days lock up a lot of working capital and could reduce cash conversion and free cash flow.
- Profit grew only 6% a year over 3 years, against a P/E of 27.9x. That implies a P/E-to-growth ratio of roughly 4.6x on 3-year growth, which leaves little margin for error.
- ROE has slipped from 21% over 5 years to 19% over 3 years and 18% last year, a gradual decline in capital efficiency.
- The stock's 45% return over the past year far outpaces its 3-year profit CAGR of 6%. This suggests much of the gain comes from a re-rating rather than underlying earnings growth.
- A P/B of 5.04x is a significant premium to book value, so the valuation depends heavily on returns staying high.
- The dividend yield of 0.36% is low, giving limited income support despite the 27.4% payout ratio.
- The 5-year stock CAGR of 15% is well below the 3-year CAGR of 30%. Returns have been uneven and depend on the time period chosen.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Brazil subsidiary incorporated Sep 16
Alivus set up a wholly owned subsidiary, Alivus Life Sciences Do Brasil Ltda, in Sao Paulo, registered on September 15, 2026, with authorized capital of R$ 500,000. The move gives the company a direct presence in Latin America's largest pharma market.
- AGM approves ₹5 dividend Sep 8
Shareholders passed all four resolutions at the 15th AGM, including a ₹5 per share dividend. Financials and a director reappointment were also approved with overwhelming support, which points to steady shareholder confidence and governance continuity.
- Kotak Healthcare Forum on Sep 17 Sep 11
Alivus will take part in the Kotak Healthcare Forum 2026 in Mumbai on September 17, 2026. The in-person event includes group and one-on-one sessions with company representatives.
- One-on-one meetings with institutional investors Sep 5
The company held one-on-one meetings with Breakout Capital, UTI, Kotak Mutual Fund and Param Capital in Mumbai on September 9, 2026. This shows ongoing institutional interest, but the disclosure says nothing about the outcome.
TL;DR: Recent news for Alivus is constructive. It entered Brazil through a new subsidiary, paid a ₹5 dividend and passed all AGM resolutions with strong support. No negative news came up in this period, but none of the items include earnings, margin or regulatory data, so they say little about how the business is actually performing. The investor meetings in September may lift institutional visibility, and the next quarterly results and any update on how the Brazil subsidiary is used will show whether the trend keeps improving.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| PBT | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Expenses | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,754 | 1,754 |
| Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 33 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| PBT | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% | — |
| Net Profit | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS in Rs | -430 | 998 | 1,597 | 359 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Div. Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Investing | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Financing | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | 0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/OP | 4,800 | 14 | 61 | 84 | 119 | 71 | 85 | 81 | 93 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | — | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alivus Life Sciences insights
65 extracted metrics + investor summaries across FY18–FY27.
Documents
Frequently Asked Questions about Alivus Life Sciences
What does Alivus Life Sciences Ltd do?
Where is Alivus Life Sciences Ltd (ALIVUS) listed?
Which sector does Alivus Life Sciences Ltd belong to?
What is the market capitalisation of Alivus Life Sciences Ltd?
What is the PE ratio of Alivus Life Sciences Ltd?
What is the 52-week high and low of Alivus Life Sciences Ltd?
Does Alivus Life Sciences Ltd pay dividends?
What is the Return on Equity (ROE) of Alivus Life Sciences Ltd?
Company Information
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALIVUS.md for Alivus Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.